Page last updated: 2024-10-30

mebendazole and Myasthenia Gravis

mebendazole has been researched along with Myasthenia Gravis in 1 studies

Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.
mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.

Myasthenia Gravis: A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Krcméry, V1
Gould, I1
Sobota, K1
Spánik, S1

Other Studies

1 other study available for mebendazole and Myasthenia Gravis

ArticleYear
Two cases of disseminated toxocariasis in compromised hosts successfully treated with mebendazole.
    Chemotherapy, 1992, Volume: 38, Issue:5

    Topics: Adrenal Cortex Hormones; Adult; Animals; Female; Humans; Immunocompromised Host; Male; Mebendazole;

1992